Tissue Engineered Skin Substitutes Market

Tissue engineering is a method of restoring, improving, maintaining damaged organs and tissues. It helps in developing functional tissues as an option to natural ones by using a combination of biologically active molecules, scaffolds, and cells. The development of skin substitutes occurs through using non-human tissue or human tissue, or a combination of both. These techniques are commonly used for treating chronic wounds, acute wounds, and treat burns among others.

There are several factors that are helping to drive the growth of the global tissue engineered skin substitute market. One of the important driving factors for the market is the rising number of patients who are suffering from vascular ulcers and diabetic ulcers who need tissue engineered skin substitute. Another important driving factor for the market development has been increasing demand for minimally invasive surgical procedures. More and more people are inclined towards these non-invasive surgical procedures as they are less painful, easy to operate, and early and quick recovery. Furthermore, the market growth is also helped by the growing geriatric demographic across the globe who face different ailments and need help of tissue engineered skin substitute.

Based on type of, the global tissue engineered skin substitute is segmented into cellular autologous, cellular allogenic, acellular, and others. The segment of cellular autologous is expected to witness a promising rate of growth in the coming years of the forecast period.

Based on the application, the global tissue engineered skin substitute market is segmented into burns, diabetic ulcers, vascular ulcers, and others. The segment of burns is expected to witness a flourishing growth in the coming years of the forecast period as the prevalence of physical trauma incidents is on the rise. Increasing prevalence of diabetes and cardiovascular disorders is a key factor in pushing growth of the diabetic/vascular ulcers segment.

Tissue Engineered Skin Substitutes Market: Snapshot 

The elderly are highly prone to contracting skin diseases such as various forms of ulcers due to their significantly reduced flow of blood and overall immunity against diseases. The number of geriatrics in all nations has been on the rise owing to multiple factors, and a rise in their number is a direct call to action for all related healthcare organizations, products, and services. This includes the tissue engineered skin substitute providers and makes the above the top driver for its market.

The number of patients suffering from skin diseases and ulcers is also increasing within younger demographics. The CDC, for instance, stated in 2015 that close to 900,000 people are affected by DVT per year. A large number of patients were additionally being diagnosed with venous diseases per year, further boosting the need for tissue engineered skin substitutes.

The market is, however, restrained by over competitiveness between local manufacturers and their globally prominent counterparts. The local manufacturers can offer tissue engineered skin substitutes at a much lower price than global ones, forcing the latter to drop prices and consequently their profit margins. This will affect the market’s rate of research and development in the long run.

These drivers and restraints are expected to converge to result in a CAGR of 17.2% for the global market of tissue engineered skin substitutes between 2015 and 2023. This market is expected to be valued at US$1.24 bn by the end of 2016, and US$3.87 bn by 2023.

North America Continues to Show Strong Demand for Tissue Engineered Skin Substitutes

The need for tissue engineered skin substitutes in North America has consistently been high over the past few years. It is expected to generate US$1.96 bn in revenue for tissue engineered skin substitute players by 2023. A key reason prompting the use of tissue engineered skin substitutes in North America is the very high prevalence of vascular diseases. The region holds an especially high proportion of the geriatric, diabetic, and obese demographics and thus requires tissue engineered skin substitutes to a higher degree than other major regions.

Europe is another key region for tissue engineered skin substitute players. This region shows a similarly high demand as that shown by North America, although at a smaller revenue cap. The highest demand for tissue engineered skin substitutes at the moment, however, comes from Asia Pacific. The revenue earned by tissue engineered skin substitute providers in this region is expected to progress at a CAGR of 18.3% from 2015 to 2023. Key reasons for the high proliferation of tissue engineered skin substitute players in Asia Pacific is the growing geriatric population in nations such as South Korea and Japan, along with the rapidly increasing investments made by governments into the market.

Tissue Engineered Skin Substitutes to Find Increasing Demand in Treatment of Ulcers

Ulcers have consistently been the leading application segment for tissue engineered skin substitutes. By the end of 2023, nearly US$2.1 bn will be generated by tissue engineered skin substitute players through ulcer treatment alone. This segment is also expected to grow at a robust CAGR of 17.5% within 2015 and 2023.

The same applies to other skin disorders that are growing in prevalence across the globe. Most dermatology organizations such as the ADA have made their predictions, all of which point to a growing number of patients with skin disorders. The ADA, for instance, in 2013, released findings of a study that stated at least one in every five U.S. citizens will suffer from a skin disorder in their lifetime. This makes the development of dermatology solutions such as tissue engineered skin substitutes a matter of high concern.

The key manufacturers of tissue engineered skin substitutes include Acelity, Smith & Nephew, Molnlycke, ConVatec, Medtronic, and BSN Medical.